Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) CEO Sells 4,486 Shares of Stock

Key Points

• CEO Jurgi Camblong sold 4,486 shares on April 20 at an average price of $5.21 under a pre‑arranged Rule 10b5‑1 plan to cover tax withholding, leaving him with 3,642,481 shares (a 0.12% ownership decline).
• Across March–April Camblong executed multiple insider sales totaling about 96,000 shares for roughly $472,000 in proceeds, according to SEC filings and company disclosures.
• SOPH traded at $5.12 (down 1.3%) with a market cap of about $350.7M; the company reported an EPS loss (-$0.28) that missed estimates, and analysts are mixed with a consensus "Hold" and a $7.50 price target.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CEO Jurgi Camblong sold 4,486 shares of the company's stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $5.21, for a total value of $23,372.06. Following the completion of the transaction, the chief executive officer owned 3,642,481 shares of the company's stock, valued at $18,977,326.01. The trade was a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Wednesday, April 15th, Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.00, for a total value of $87,365.00.
• On Tuesday, April 14th, Jurgi Camblong sold 43,129 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.96, for a total value of $213,919.84.
• On Monday, April 13th, Jurgi Camblong sold 4,399 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total value of $20,939.24.
• On Friday, April 10th, Jurgi Camblong sold 12,232 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.72, for a total value of $57,735.04.
• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total transaction of $9,243.00.
• On Wednesday, April 8th, Jurgi Camblong sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total transaction of $13,552.00.
• On Tuesday, April 7th, Jurgi Camblong sold 2,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.86, for a total transaction of $12,150.00.
• On Monday, April 6th, Jurgi Camblong sold 2,600 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total transaction of $12,610.00.
• On Thursday, March 19th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.77, for a total transaction of $21,398.22.

SOPHiA GENETICS Stock Down 1.3%

NASDAQ SOPH traded down $0.07 during trading hours on Tuesday, reaching $5.12. 165,976 shares of the company's stock traded hands, compared to its average volume of 180,131. SOPHiA GENETICS SA has a 52-week low of $2.59 and a 52-week high of $5.70. The firm has a market cap of $350.65 million, a PE ratio of -10.04 and a beta of 1.04. The firm has a 50-day simple moving average of $4.77 and a 200 day simple moving average of $4.73. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.96 and a quick ratio of 1.84.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. The business had revenue of $21.71 million for the quarter, compared to analysts' expectations of $21.20 million.

Wall Street Analyst Weigh In

A number of research firms have weighed in on SOPH. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. BTIG Research raised their price objective on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Wednesday, April 15th. Finally, Guggenheim raised their price objective on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a "buy" rating in a research note on Monday, January 26th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, SOPHiA GENETICS currently has an average rating of "Hold" and a consensus price target of $7.50.

Institutional Trading of SOPHiA GENETICS

A number of large investors have recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock valued at $25,341,000 after buying an additional 5,432,871 shares during the period. Federated Hermes Inc. grew its position in SOPHiA GENETICS by 16.4% during the second quarter. Federated Hermes Inc. now owns 220,000 shares of the company's stock valued at $682,000 after buying an additional 31,000 shares during the period. Akre Capital Management LLC grew its position in SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock valued at $11,529,000 after buying an additional 1,481,636 shares during the period. Alta Wealth Advisors LLC bought a new stake in SOPHiA GENETICS during the third quarter valued at approximately $6,708,000. Finally, Savvy Advisors Inc. bought a new stake in SOPHiA GENETICS during the third quarter valued at approximately $48,000. 31.59% of the stock is currently owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.